~~<i id='4E8F2829D5'><strike id='4E8F2829D5'><tt id='4E8F2829D5'><pre id='4E8F2829D5'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：hotspot 2025-10-02 01:39:41 Page View：7667

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Software glitch causes Tandem insulin pump to shutdown, FDA warns
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

MARCOBERTORELLO/AFPviaGettyImagesIn1995,whenMarionNestlewasonthecommitteedraftingtheDietaryGuideline

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Sanofi strikes deal with Novavax, boosting the vaccine maker

NICOLASMAETERLINCK/BELGAMAG/AFPviaGettyImagesLONDON—Novavax,thebeleagueredmakerofaCovid-19vaccine,ju